If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D




Comment for Type of Reporting Person:
(1) Consists of (i) 58,023 shares of Class A Common Stock held directly by Daewoong Co., Ltd. ("DWC") and (ii) 23,184,523 shares of Class A Common Stock held directly by Daewoong Pharmaceutical Co., Ltd. ("DWP"). DWC owns approximately 52% of the outstanding shares of DWP and may be deemed to beneficially own the securities held directly by DWP. The amounts set forth above do not include 8,000,000 shares of Class A Common Stock issuable upon exercise of the Common Stock Warrant held directly by DWP or the shares of Class A Common Stock issuable upon conversion of the Senior Secured Convertible Note held directly by DWP, each as described in Item 5(a). (2) Based on 76,009,476 shares of Class A Common Stock outstanding as of November 9, 2026, as confirmed to the Reporting Persons by the Issuer.


SCHEDULE 13D




Comment for Type of Reporting Person:
(1) Consists of 23,184,523 shares of Class A Common Stock held directly by Daewoong Pharmaceutical Co., Ltd. ("DWP"). The amounts set forth above do not include 8,000,000 shares of Class A Common Stock issuable upon exercise of the Common Stock Warrant held directly by DWP or the shares of Class A Common Stock issuable upon conversion of the Senior Secured Convertible Note held directly by DWP, each as described in Item 5(a). (2) Based on 76,009,476 shares of Class A Common Stock outstanding as of November 9, 2026, as confirmed to the Reporting Persons by the Issuer.


SCHEDULE 13D


 
Daewoong Co., Ltd.
 
Signature:/s/ Bumseok Kim
Name/Title:Bumseok Kim/Authorized Signatory
Date:11/10/2026
 
Daewoong Pharmaceutical Co., Ltd.
 
Signature:/s/ Seung Hoon Lee
Name/Title:Seung Hoon Lee/Authorized Signatory
Date:11/10/2026